Form 8-K - Current report:
SEC Accession No. 0001213900-24-040955
Filing Date
2024-05-09
Accepted
2024-05-08 18:30:38
Documents
13
Period of Report
2024-05-08
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea020556601-8k_cadrenal.htm   iXBRL 8-K 29873
  Complete submission text file 0001213900-24-040955.txt   206745

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cvkd-20240508.xsd EX-101.SCH 3060
3 XBRL LABEL FILE cvkd-20240508_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE cvkd-20240508_pre.xml EX-101.PRE 22389
16 EXTRACTED XBRL INSTANCE DOCUMENT ea020556601-8k_cadrenal_htm.xml XML 3801
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 24927897
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)